AstraZenecca – Bullish trend is still intact

AstraZeneca, the biopharmaceutical company, said that “the Company has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020"

Uptrend 2

AstraZeneca, the biopharmaceutical company, said that “the Company has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020. AstraZeneca today received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in the fall."


AstraZeneca recalls joining forces with the British government to support the Oxford University vaccine. It is also working with international organizations, including the WHO, to distribute the vaccine worldwide.

From a chartist’s point of view, the stock price remains within a short term bullish channel, supported by the 20-day simple moving average currently at 8,550p. Bollinger bands confirm the bullish trend. However, the Relative Strength Index (RSI, 14) has broken down its overbought area at 70% indicating that a consolidation move could be on the cards. First support threshold is set at 8,522p (Horizontal level + Channel lower boundary). 

As long as 8,048 is support, readers may want to take advantage of any pullback as an opportunity to open long positions with 9,000p and 9,600p as targets.
Alternatively, a break below 8,048 would call for a reversal down trend towards 7,300p.

Souce: GAIN Capital, TradingView


Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.

Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to Forex.com or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.